Pediatric Crohn's disease (CD) is associated with high circulating concentrations of pro-inflammatory cytokines (IL-6, TNF-α) and acute phase proteins (CRP). These proteins can cross the blood-brain-barrier. For example, IL-6 is expressed in the hippocampus, hypothalamus and cortex, TNF-α in microglia. Thus, excess cytokines have the potential to disrupt brain systems critical for memory, executive functions and mood. Children with CD therefore may be at particular risk for cognitive and emotional problems based on not only short and long-term medication regimens, but their underlying disease itself. Our earlier reports of behavioral impact of inflammation have been confounded by the fact that patients were concurrently treated with corticosteroids, which can cause similar behavioral and CNS side-effects. We here investigate the effects of inflammation on memory and executive functions independent of steroids. Behavioral and cytokine data from an ongoing NIH study were available on 61 children with CD age 8-16 years who have completed the study thus far. Patients were assessed at one time-point of a longitudinal design, when all were off steroids for at least 4-6 months. Standardized measures of memory, executive functions, IQ, mood, sleep, and pain severity were administered. Questionnaires included the Behavior Rating of Executive Functions (BRIEF), Child Behavior Checklist (CBCL), Youth Self Report (YSR), and Children's Depression Inventory (CDI). Serum markers of inflammation included high-sensitivity C-reactive protein (hsCRP) and pro-inflammatory cytokines/receptors (IL-6, TNFR2). Higher levels of inflammation in patients with CD were variably associated with poorer neurobehavioral outcome, as indicated by parent and selfreport of cognitive and mood problems in daily life. TNFR2 emerged as the most robust predictor for executive problems, which were primarily of cognitive nature (see table). Effects remained after adjusting for pain, sleep, IQ, and prior steroid therapy. Correlations were modest but consistent with the literature. There was no sizable effect on laboratory cognitive measures. Results replicate earlier findings of the impact of inflammation on cognition and mood in children with CD. Higher levels of inflammation were associated with more reported problems in executive functions, including difficulties in controlling one's behavior, getting started on or completing tasks, working efficiently, as well as in attention and working memory. These functions are presumably mediated by prefrontal cortex, limbic system and potentially interconnecting white matter. While few effects were found on laboratory cognitive tests, patients and parents reported more cognitive problems in daily life associated with higher inflammatory markers. This discrepancy between test and questionnaire results in populations without frank neurological impairment is a known phenomenon in neuropsychological research, and one that is likely best addressed with the use of more sensitive neural measures such as neuroimaging. Clinically, these findings carry important implications for patient education, that underlying chronic inflammation, especially when untreated, can have far reaching developmental impact.